The first patient has been treated with ruxolitinib (Jakafi), by Incyte Corporation, for steroid-refractory acute graft-versus-host disease, as part of the REACH-1 phase 2 trial. The trial is evaluating ruxolitinib in combination with corticosteroids.
The first patient has been treated with ruxolitinib (Jakafi), by Incyte Corporation, for steroid-refractory acute graft-versus-host disease (GVHD), as part of the REACH-1 phase 2 trial. The trial is evaluating ruxolitinib in combination with corticosteroids.
GVHD, a significant cause of morbidity and mortality in transplant recipients, can occur after an allogeneic transplant. In GVHD, the donated bone marrow or peripheral blood stem cells attack the body. The condition is very rare, occurring in fewer than 20,000 people in the United States each year.
“We are very pleased to have the first patient treated in the pivotal trial program for ruxolitinib in GVHD, a severe and often life-threatening condition for which there are currently no approved treatments,” Steven Stein, MD, Incyte’s chief medical officer, said in a statement. “We look forward to building on the clinical evidence to-date for ruxolitinib and working with regulators to help address the urgent needs of these patients.”
There are 2 forms of GVHD: acute and chronic. With acute GVHD, the skin, the gastrointestinal tract, and the liver are most commonly affected. Ruxolitinib has been granted Breakthrough Therapy Designation for the treatment of acute GVHD by the FDA. It has also been granted Orphan Drug Designation for the treatment of GVHD.
REACH-1 is a single-cohort phase 2 study that is sponsored by Incyte. It is also expected to include collaborative Novartis-sponsored pivotal studies in steroid-refractory acute GVHD and steroid-refractory chronic GVHD. The Novartis-sponsored studies are expected to begin early this year.
Ruxolitinib is a first-in-class JAK1/JAK2 inhibitor. It is already approved for treatment of people with polycythemia vera and is indicated for treating people with intermediate or high-risk myelofibrosis. In the United States, the drug is marketed as Jakafi by Incyte, but outside of the US, it is marketed as Jakavi by Novartis.
Common side effects of Jakafi are low blood counts, infection, skin cancers, and increases in cholesterol.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More